Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 423-428

  He, Qing ^a   Engelson, Ellen S ^a   Ionescu, Gabriel ^a   Glesby, Marshall J ^b   Albu, Jeanine B ^a   Kotler, Donald P ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LIPID; ANTIRETROVIRUS AGENT;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL FOR ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LINEAR REGRESSION ANALYSIS; LIPID LIVER LEVEL; MALE; MESENTERY; MUSCLE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OMENTUM; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RATING SCALE; RETROPERITONEUM; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS FAT; UNIVARIATE ANALYSIS; BIOLOGICAL MODEL; BLOOD; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; LIPID METABOLISM; LIVER; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADIPOSITY; ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SUBCUTANEOUS FAT; TREATMENT OUTCOME;

EID: 47249098605     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
2. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
3. Engelson ES, Kotier DP, Tan Y, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999; 69:1162-1169.
4. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
5. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001; 15:1993-2000.
6. He Q, Engelson ES, Albu JB, et al. Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy. J Appl Physiol 2003; 94:2051-2057.
7. Bodkin NL, Metzger BL, Hansen BC. Hepatic glucose production and insulin sensitivity preceding diabetes in monkeys. Am J Physiol 1989; 56:E676-E681.
8. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001; 24:89-94.
9. Zethelius B, Hales CN, Lithell HO, Berne C. Insulin resistance, impaired early insulin response, and insulin propeptides as predictors of the development of type 2 diabetes: a population-based, 7-year follow-up study in 70-year-old men. Diabetes Care 2004; 27:1433-1438.
10. Seppälä Lindroos A, Vehkavaara S, Häkkinen AM, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002; 87:3023-3028.
11. 1H-MR spectroscopy. Antivir Ther 2007; 12:195-203.
12. Sutinen J, Häkkinen AM, Westerbacka J, et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16:2183-2193.
13. Hadigan C, Liebau J, Andersen R, et al. Magnetic resonance spectroscopy of hepatic lipid content and associated risk factors in HIV infection. J Acquir Immune Defic Syndr 2007; 46:312-317.
14. Gallagher D, Kuznia P, Heshka S, et al. Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. Am J Clin Nutr 2005; 81:903-910.
15. Yim JE, Heshka S, Albu J, et al. Intermuscular adipose tissue rivals visceral adipose tissue in independent associations with cardiovascular risk. Int J Obes 2007; 31:1400-1405.
16. Albu JB, Kenya S, He Q, et al. Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr 2007; 86:100-106.
17. Szczepaniak LS, Babcock EE, Schick F, et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 1999; 276:E977-E989.
18. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288:E462-E468.
19. Nielsen S, Guo Z, Johnson CM, et al. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113:1582-1588.
20. Lam TK, van de Werve G, Giacca A. Free fatty acids increase basal hepatic glucose production and induce hepatic insulin resistance at different sites. Am J Physiol Endocrinol Metab 2003; 284:E281-E290.
21. Tripathy D, Almgren P, Tuomi T, Groop L. Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 2004; 27:2204-2210.
22. Lam TK, Carpentier A, Lewis GF, et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003; 284:E863-E873.
23. Jacob S, Machann J, Rett K, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 1999; 48:1113-1119.
24. Kuhlmann J, Neumann-Haefelin C, Belz U, et al. Correlation between insulin resistance and intramyocellular lipid levels in rats. Magn Reson Med 2005; 53:1275-1282.
25. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005 54:122-127.
26. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity Diabetes Care 2000; 23:57-63.
27. Charbonneau A, Couturier K, Gauthier MS, Lavoie JM Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training. Int J Sports Med 2005; 26:432-441.
28. Tiikkainen M, Häkkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53:2169-2176.
29. Juurinen L, Tiikkainen M, Häkkinen AM, et al. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab 2007; 292:E829-E835.
30. Petersen KF, Dufour S, Befroy D, et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54:603-608.
31. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51:797-802.
32. Lessard SJ, Rivas DA, Chen ZP, et al. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance. Diabetes 2007; 56:1856-1864.